Detalhe da pesquisa
1.
Establishment of a t(11;19), KMT2A Rearranged B-ALL Cell Line for Preclinical Evaluation and Novel Therapeutics Development for Refractory Infant Leukemia.
J Pediatr Hematol Oncol
; 45(6): e750-e756, 2023 08 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37494611
2.
The Small-Molecule E26-Transformation-Specific Inhibitor TK216 Attenuates the Oncogenic Properties of Pediatric Leukemia.
Genes (Basel)
; 14(10)2023 10 08.
Artigo
Inglês
| MEDLINE | ID: mdl-37895265